




Instance: composition-en-6c515aae840296fe980507ee7ecb6244
InstanceOf: CompositionUvEpi
Title: "Composition for yargesa Package Leaflet"
Description:  "Composition for yargesa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6c515aae840296fe980507ee7ecb6244)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - yargesa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Yargesa is and what it is used for </li>
<li>What you need to know before you take Yargesa </li>
<li>How to take Yargesa </li>
<li>Possible side effects </li>
<li>How to store Yargesa </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What yargesa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What yargesa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yargesa contains the active substance miglustat which belongs to a group of medicines that affect 
metabolism. It is used to treat two conditions: </p>
<ul>
<li>Yargesa is used to treat mild to moderate type 1 Gaucher disease in adults. 
In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It 
starts to build up in certain cells of the body s immune system. This can result in liver and spleen 
enlargement, changes in the blood and bone disease. </li>
</ul>
<p>The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Yargesa is only used 
when a patient is considered unsuitable for treatment with enzyme replacement therapy. </p>
<ul>
<li>Yargesa is also used to treat progressive neurological symptoms in Niemann-Pick type C 
disease in adults and in children. 
If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your 
brain. This can result in disturbances in neurological functions such as slow eye movements, balance, 
swallowing, and memory, and in seizures. </li>
</ul>
<p>Yargesa works by inhibiting the enzyme called  glucosylceramide synthase  which is responsible for 
the first step in the synthesis of most glycosphingolipids. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Yargesa 
- if you are allergic to miglustat or any of the other ingredients of this medicine (listed in section 
6) </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Yargesa 
* if you suffer from kidney disease 
* if you suffer from liver disease 
Your doctor will perform the following tests before treatment and during treatment with Yargesa 
* an examination to check the nerves in your arms and legs 
* measurement of vitamin B12 levels 
* monitoring growth if you are a child or adolescent with Niemann-Pick type C disease 
* monitoring of blood platelet counts 
The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or 
a decrease in body weight, while taking this medicine. The tests will help the doctor decide whether 
these effects are due to your disease or other existing conditions, or due to side effects of Yargesa (see 
section 4 for further details). 
If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and 
carbohydrate intake such as sucrose (cane sugar), or not to take Yargesa together with food, or to 
temporarily reduce your dose. In some cases the doctor may prescribe anti-diarrhoeal medicines such 
as loperamide. If your diarrhoea does not respond to these measures, or if you have any other 
abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct further 
investigations. </p>
<p>Male patients should use reliable birth control methods during their treatment with Yargesa and for 3 
months after finishing treatment. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher 
disease because it is not known if it works in this disease. </p>
<p>Other medicines and Yargesa 
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines. 
Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the 
same time as Yargesa. They may lower the amount of Yargesa in your body. </p>
<p>Pregnancy, breast-feeding and fertility 
You should not take Yargesa if you are pregnant or thinking of becoming pregnant. Your doctor can 
give you more information. You must use effective birth control while taking Yargesa. Do not 
breast-feed while you are taking Yargesa. 
Male patients should use reliable birth control methods during their treatment with this medicine and 
for 3 months after finishing treatment. </p>
<p>If you are pregnant, breast feeding, think you may be pregnant or planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
Yargesa may make you feel dizzy. Do not drive or use any tools or machines if you feel dizzy. </p>
<p>Yargesa contains sodium 
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say 
essentially 'sodium-free'. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if 
you are not sure. 
Dose 
* For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a 
day(morning, afternoon and evening). This means a daily maximum of three capsules (300 mg). 
* For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual 
dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means 
a daily maximum of six capsules (600 mg). 
For children less than 12 years old, your doctor will adjust the dose for Niemann-Pick type C disease. 
If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may 
reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when 
taking Yargesa (see section 4). Your doctor will tell you how long your treatment will last. </p>
<p>To remove the capsule: 
1. Separate at perforations 
2. Peel back paper at arrows 
3. Push product through foil </p>
<p>Yargesa can be taken with or without food. You should swallow the whole capsule with a glass of 
water. </p>
<p>If you take more Yargesa than you should 
If you take more capsules than you were told to, consult your doctor immediately. Miglustat has been 
used in clinical trials at doses up to 3000 mg : this caused decreases in white blood cells and other 
side effects similar to those described in section 4. If you forget to take Yargesa </p>
<p>Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Yargesa 
Do not stop taking this medicine without talking to your doctor. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Most serious side effects 
Some patients have had tingling or numbness in the hands and feet (seen commonly). They could 
be signs of peripheral neuropathy, due to side effects of Yargesa or they could be due to existing 
conditions. Your doctor will perform some tests before and during treatment with Yargesa to assess 
this (see section 2). </p>
<p>If you do get any of these effects, please seek medical advice from your doctor as soon as 
possible. 
If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon 
as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor 
will need to reduce the dose or stop Yargesa treatment to stop the tremor. </p>
<p>Very common effects (may affect more than 1 in 10 people) 
The most common side effects are diarrhoea, flatulence (wind), abdominal (stomach) pain, weight loss 
and decreased appetite. </p>
<p>If you do lose some weight when you start treatment with Yargesa don t worry. People usually stop 
losing weight as treatment goes on. </p>
<p>Common effects (may affect up to 1 in 10 people) 
Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), 
abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea 
(feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and 
thrombocytopenia (reduced levels of blood platelets).The neurological symptoms and 
thrombocytopenia could be due to the underlying disease. </p>
<p>Other possible side effects are muscular spasms or weakness, fatigue, chills and malaise, depression, 
difficulty sleeping, forgetfulness and reduced libido. 
Most patients get one or more of these side effects, usually at the start of treatment or at intervals 
during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause 
problems, consult your doctor. He or she may reduce the dose of Yargesa or recommend other 
medicines to help control side effects. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system<br />
listed in Appendix V. By reporting side effects you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not take this medicine after the expiry date which is stated on the blister and carton after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer take. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Yargesa contains 
- the active substance is miglustat. Each hard capsule contains 100 mg miglustat. 
- the other ingredients are: 
capsule content: sodium starch glycolate (type A), povidone (K-29/32), magnesium stearate 
capsule shell: gelatin, titanium dioxide (E171) 
printing ink: shellac, iron oxide black (E172),propylene glycol, concentrated ammonia solution </p>
<p>What Yargesa looks like and contents of the pack 
Yargesa is a white hard capsule that consists of an opaque white cap and body with  708  printed in 
black on the body. Capsule size is 4 (14.3 mm x 5.3 mm). The capsules are presented in a PVC and 
polychlorotrifluoroethylene (PCTFE) perforated unit dose blister sealed with aluminium foil. 
Pack size of 84 x 1 hard capsules. 
Marketing Authorisation Holder and Manufacturer 
Piramal Critical Care B.V. 
Rouboslaan 32 (ground floor) 
2252 TR, Voorschoten 
The Netherlands </p>
<p>This leaflet was last revised in 
Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-6c515aae840296fe980507ee7ecb6244
InstanceOf: CompositionUvEpi
Title: "Composition for yargesa Package Leaflet"
Description:  "Composition for yargesa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6c515aae840296fe980507ee7ecb6244)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - yargesa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Yargesa 
3. Sådan skal De tage Yargesa 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What yargesa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What yargesa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yargesa indeholder det aktive stof miglustat, som tilhører en gruppe af lægemidler, som påvirker 
stofskiftet. Det anvendes til behandling af to tilstande: </p>
<p>• Yargesa anvendes til behandling af let til moderat Gauchers sygdom, type 1, hos voksne. 
Ved Gauchers sygdom, type 1 er der et stof kaldet glucosylceramid, som ikke fjernes fra kroppen. Det 
ophobes i visse celler i kroppens immunsystem. Dette kan medføre forstørrelse af lever og milt, 
forandringer i blodet og knoglesygdom. 
Den almindelige behandling af Gauchers sygdom, type 1 er enzymsubstitutionsterapi. Yargesa 
anvendes kun, når en patient anses for uegnet til behandling med enzymsubstitutionsterapi. </p>
<p>• Yargesa anvendes også til behandling af fremadskridende neurologiske symptomer ved 
Niemann-Picks sygdom, type C, hos voksne og børn. 
Hvis De har Niemann-Picks sygdom, type C, ophobes fedt f.eks. glycosphingolipider i cellerne i Deres 
hjerne. Det kan resultere i forstyrrelser i neurologiske funktioner som f.eks. langsomme 
øjenbevægelser, balance, synkning og hukommelse samt i krampeanfald. 
Yargesa virker ved at hæmme et enzym, som kaldes ’glucosylceramidsyntase’, som er ansvarlig for det 
første trin i omdannelsen af de fleste glycosphingolipider. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Yargesa 
- hvis De er allergisk over for miglustat eller et af de øvrige indholdsstoffer i Yargesa (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Yargesa, 
- hvis De lider af en nyresygdom 
- hvis De lider af en leversygdom 
Deres læge vil gennemføre følgende tests, før og under behandling med Yargesa:</p>
<ul>
<li>en undersøgelse for at kontrollere nerverne i Deres arme og ben </li>
<li>måling af vitamin B12-niveauerne </li>
<li>kontrollere Deres vækst, hvis De er barn eller ung med Niemann-Picks sygdom, type C. </li>
<li>kontrollere antallet af blodplader 
Årsagen til disse prøver er, at visse patients har snurren eller følelsesløshed i hænder og fødder, eller 
taber i vægt, når de tager denne medicin . Prøverne vil hjælpe lægen til at beslutte, om disse virkninger 
skyldesDeres sygdom eller eksisterende tilstande eller er bivirkninger af Yargesa (se punkt 4 for nærmere 
oplysninger). 
Hvis De har diarré, vil Deres læge måske bede Dem om følgende: At De ændrer Deres kost for at 
reducere indtagelsen af lactose og kulhydrater såsom sukrose (sukker), at De ikke tager Yargesa 
sammen med måltider, eller at De nedsætter Deres dosis midlertidigt. I nogle tilfælde vil lægen 
ordinere et lægemiddel mod diarré, for eksempel loperamid. Henvend Dem til Deres læge, hvis Deres 
diarré ikke reagerer på disse foranstaltninger, eller hvis De har andre maveproblemer. Hvis det er 
tilfældet vil Deres læge muligvis beslutte, at der skal gennemføres flere undersøgelser. 
Mandlige patienter bør anvende pålidelige præventionsmidler under behandling med Yargesa og i 
3 måneder efter, at behandlingen er afsluttet. </li>
</ul>
<p>Børn og unge 
Giv ikke denne medicin til børn og teenagere (under 18 år) med Gauchers sygdom, type 1, da det ikke 
vides, om den virker. </p>
<p>Brug af anden medicin sammen med Yargesa 
Fortæl altid lægen eller på apoteket, hvis De tager anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler og vitaminer og mineraler. 
Fortæl det til lægen, hvis De tager lægemidler, der indeholder imiglucerase, som nogle gange bruges 
samtidigt med Yargesa. Imiglucerase kan nedsætte mængden af Yargesa i kroppen. 
Graviditet, amning og frugtbarhed 
De må ikke tage Yargesa, hvis De er gravid, eller hvis De overvejer at blive gravid. Deres læge kan 
give Dem yderligere oplysninger. De skal benytte effektiv prævention, mens De tager Yargesa. De må 
ikke amme, mens De tager Yargesa. 
Mænd skal anvende sikker prævention under behandlingen og i 3 måneder efter, behandlingen med 
denne medicin er afsluttet. </p>
<p>Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apoteket til råds, før De tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Yargesa kan forårsage svimmelhed. Lad være med at køre bil eller arbejde med værktøj eller maskiner, 
hvis De føler Dem svimmel. </p>
<p>Yargesa indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. kapsel, det vil sige i det 
væsentlige "natriumfrit". </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Dosis </p>
<ul>
<li>
<p>Ved Gauchers sygdom, type 1: Til voksne er den sædvanlige dosis én kapsel (100 mg) tre 
gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt tre kapsler (300 mg) om 
dagen. </p>
</li>
<li>
<p>Ved Niemann-Picks sygdom, type C: Til voksne og unge (over 12 år) er den sædvanlige dosis 
på to kapsler (200 mg) tre gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt 
seks kapsler (600 mg) om dagen. 
Lægen vil tilpasse dosis hos børn under 12 år med Niemann-Picks sygdom, type C. 
Hvis De har problemer med Deres nyrer, skal De muligvis starte med en lavere dosis. Hvis De lider af 
diarré under behandlingen med Yargesa, vil Deres læge muligvis sætte Deres dosis ned, f.eks. til én 
kapsel (100 mg) én eller to gange dagligt (se punkt 4). Deres læge vil fortælle Dem, hvor længe 
behandlingen skal vare. </p>
</li>
</ul>
<p>Udpakning af kapslen: 
1. Adskil ved perforeringerne 
2. Træk papiret tilbage ved pilene 
3. Tryk produktet gennem folien </p>
<p>Yargesa kan tages sammen med eller uden mad. De skal synke kapslen hel med et glas vand. </p>
<p>Hvis De har taget for mange Yargesa 
Hvis De tager flere kapsler, end De har fået besked på, skal De straks søge læge. Miglustat er blevet 
anvendt i kliniske forsøg med doser til 3 000 mg : Dette medførte et fald i antallet af hvide blodlegemer 
og andre bivirkninger svarende til dem, der er beskrevet i punkt 4. Hvis De har glemt at tage Yargesa 
Tag den næste kapsel til sædvanlig tid. De må ikke tage en dobbeltdosis som erstatning for den glemte 
dosis. 
Hvis De holder op med at tage Yargesa 
Stop ikke med at tage denne medicin uden at rådføre Dem med lægen. 
Spørg lægen eller apotekspersonalet, hvis der er noget De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Mest alvorlige bivirkninger: 
Nogle patienter har haft snurren eller følelsesløshed i hænder og fødder (almindelig bivirkning). 
Dette kan være tegn på perifer neuropati, som skyldes bivirkninger af Yargesa, eller det kan være på 
grund af eksisterende lidelser. Deres læge vil gennemføre nogle prøver før og under behandling med 
Yargesa for at bedømme dette (se punkt 2). 
Hvis De får nogle af disse bivirkninger, skal De søge rådgivning hos lægen så hurtigt som muligt. 
Hvis De får en let rysten, sædvanligvis af hænderne, skal De søge rådgivning hos lægen så hurtigt </p>
<p>som muligt. Denne rysten forsvinder ofte, uden at det er nødvendigt at stoppe behandlingen. Af og til 
vil det være nødvendigt for lægen at nedsætte dosis eller stoppe behandlingen med Yargesa for at 
stoppe denne rysten. </p>
<p>Meget almindelige bivirkninger - kan forekomme hos flere end 1 ud af 10 behandlede 
De almindeligste bivirkninger er diarré, flatulens (luft i maven), mavesmerter, vægttab og nedsat 
appetit. 
Hvis De taber i vægt, når De starter behandling med Yargesa, skal De ikke blive bekymret. Normalt 
ophører vægttabet ved fortsat behandling. </p>
<p>Almindelige bivirkninger - kan forekomme hos op til 1 ud af 10 behandlede 
Almindelige bivirkninger af behandlingen omfatter hovedpine, svimmelhed, paræstesi (snurrende 
fornemmelse eller følelsesløshed), koordinationsforstyrrelser, hypoæstesi (nedsat følesans), 
fordøjelsesbesvær (halsbrand), kvalme (utilpashed), forstoppelse og opkastning, hævelse eller ubehag i 
underlivet (maven) og trombocytopeni (nedsat antal blodplader). De neurologiske symptomer og 
trombocytopeni kan skyldes den underliggende sygdom. 
Andre mulige bivirkninger er muskelkramper eller -svaghed, træthed, kulderystelser og utilpashed, 
depression, søvnbesvær, glemsomhed og nedsat lyst til sex (libido). 
De fleste patienter oplever en eller flere af disse bivirkninger, i reglen i starten af behandlingen eller 
med mellemrum under behandlingen. De fleste tilfælde er lette og forsvinder ret hurtigt. Hvis nogle af 
disse bivirkninger giver anledning til problemer, skal De rådføre Dem med lægen. Han eller hun kan 
nedsætte Deres dosis af Yargesa eller anbefale anden medicin, der kan hjælpe med at kontrollere 
bivirkningerne. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store yargesa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store yargesa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og pakningen efter Exp. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.Spørg på apoteket, 
hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide medicinrester i 
afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yargesa indeholder:</p>
<ul>
<li>Aktivt stof: miglustat 100 mg. Hver hårde kapsel indeholder 100 mg miglustat. </li>
<li>Øvrige indholdsstoffer: </li>
</ul>
<p>kapselindhold - natriumstivelsesglycolat (type A), povidon (K-29/32), magnesiumstearat, 
kapselskal -gelatine, , titandioxid (E171), 
trykfarve -shellak , sort jernoxid (E172), propylenglycol koncentreret ammoniumopløsning. </p>
<p>Udseende og pakningsstørrelser 
Yargesa er en hvid hård kapsel, der består af en uigennemsigtig hvid overdel og underdel med "708" 
trykt i sort på underdelen. Kapselstørrelsen er 4 (14,3 mm x 5,3 mm). 
Kapslerne er pakket i en blister lavet af PVC og polychlorotrifluoroethylen (PCTFE) perforeret 
enhedsdosis, der er forsegletmed aluminiumsfolie. 
Pakningsstørrelse: 84 x 1 hårdt kapsler. 
Indehaver af markedsføringstilladelsen og fremstiller 
Piramal Critical Care B.V. 
Rouboslaan 32 (ground floor) 
2252 TR, Voorschoten 
Holland </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}&gt; &lt;{måned ÅÅÅÅ}.&gt; 
Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om Yargesa på Det Europæiske Lægemiddelagenturs hjemmeside 
http://www.ema.europa.eu/. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-6c515aae840296fe980507ee7ecb6244
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for yargesa Package Leaflet for language en"
Description: "ePI document Bundle for yargesa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6c515aae840296fe980507ee7ecb6244"
* entry[0].resource = composition-en-6c515aae840296fe980507ee7ecb6244

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6c515aae840296fe980507ee7ecb6244"
* entry[=].resource = mp6c515aae840296fe980507ee7ecb6244
                            
                    
Instance: bundlepackageleaflet-da-6c515aae840296fe980507ee7ecb6244
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for yargesa Package Leaflet for language da"
Description: "ePI document Bundle for yargesa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6c515aae840296fe980507ee7ecb6244"
* entry[0].resource = composition-da-6c515aae840296fe980507ee7ecb6244

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6c515aae840296fe980507ee7ecb6244"
* entry[=].resource = mp6c515aae840296fe980507ee7ecb6244
                            
                    



Instance: mp6c515aae840296fe980507ee7ecb6244
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Yargesa 100 mg hard capsules"
Description: "Yargesa 100 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1176/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Yargesa 100 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6c515aae840296fe980507ee7ecb6244ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "yargesa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with yargesa"

* subject = Reference(mp6c515aae840296fe980507ee7ecb6244)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#yargesa "yargesa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6c515aae840296fe980507ee7ecb6244) // yargesa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6c515aae840296fe980507ee7ecb6244) // yargesa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6c515aae840296fe980507ee7ecb6244
InstanceOf: List

* insert 6c515aae840296fe980507ee7ecb6244ListRuleset
    